Genscript Biotech revenue and financials
In the fiscal year ended December 2025, Genscript Biotech reported revenue of $959.53M (+61.40% year over year). The net loss was $532.83M.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +61.40%
- 2025 vs 2024
- Net margin
- -55.5%
- 2024: 498.2%
How Genscript Biotech is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 19.7% a year on average over the last 5 years
Compound annual growth rate: from $390.85M in 2020 to $959.53M in 2025.
Operating margin rose from −70.0% to 26.6%
Operating income over revenue, 2022 → 2025: 96.6 percentage points.
Less cash than profit: free cash flow equal to -18% of net income
Totals for fiscal years 2023–2025: free cash flow -$416.11M, net income $2.33B.
Shares outstanding up 15.3% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 1 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 960 | 594 | 560 | 626 | 490 | 391 | 273 | 231 | 153 | 115 |
| Cost of revenue | 406 | 322 | 290 | 322 | 208 | 135 | 93.1 | 72.5 | 48.1 | 38.5 |
| Gross profit | 553 | 272 | 271 | 304 | 283 | 256 | 180 | 159 | 105 | 76.2 |
| Selling, general and administrative | 227 | 209 | 192 | 352 | 303 | 197 | 126 | 79.4 | 46.9 | 51.3 |
| Research and development | 71.2 | 53.8 | 52.7 | 390 | 358 | 263 | 186 | 74.1 | 18.1 | — |
| Operating income | 255 | 9.3 | 26.2 | -438 | -379 | -205 | -131 | 5.1 | 39.6 | 24.9 |
| EBIT | 255 | 9.3 | 26.2 | -438 | -379 | -205 | -131 | 5.1 | 39.6 | 24.9 |
| EBITDA | 318 | 70.0 | 83.5 | -389 | -342 | -175 | -112 | 17.4 | 46.2 | 30.0 |
| Interest expense | 17.3 | 8.0 | 5.7 | 13.3 | 2.4 | 1.4 | 0.8 | 0.1 | — | 0.0 |
| Pre-tax income | -471 | -171 | 169 | -432 | -517 | -282 | -114 | 22.7 | 38.5 | 32.5 |
| Income tax | 61.9 | 3.0 | 6.0 | -3.7 | 1.0 | -0.5 | 3.8 | 1.9 | 11.5 | 6.0 |
| Net income | -533 | 2,962 | -95.5 | -227 | -359 | -205 | -96.9 | 21.2 | 26.1 | 26.2 |
| Net income to common shareholders | -533 | -67.2 | 423 | -227 | -359 | -205 | -96.9 | 21.2 | 26.1 | 26.2 |
| Basic EPS | -0.25 | -0.03 | 0.20 | -0.11 | -0.18 | -0.11 | -0.05 | 0.01 | 0.02 | 0.02 |
| Diluted EPS | -0.25 | -0.03 | 0.20 | -0.11 | -0.18 | -0.11 | -0.05 | 0.01 | 0.02 | 0.02 |
| Average shares (basic) | 2,167 | 2,121 | 2,109 | 2,097 | 2,031 | 1,901 | 1,854 | 1,792 | 1,714 | 1,667 |
| Average shares (diluted) | 2,192 | 2,178 | 2,109 | 2,097 | 2,031 | 1,901 | 1,854 | 1,840 | 1,729 | 1,709 |
| Dividend per share | — | — | — | — | — | — | — | — | — | 0.00 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 404 | 441 | 519 | 309 | 285 | — | 391 | 316 | 310 | 261 |
| Cost of revenue | 198 | 208 | 198 | 171 | 152 | — | 216 | 181 | 141 | 117 |
| Gross profit | 207 | 233 | 321 | 139 | 134 | — | 175 | 136 | 168 | 144 |
| Selling, general and administrative | 117 | 117 | 111 | 107 | 95.8 | — | 188 | 184 | 167 | 188 |
| Research and development | 39.4 | 39.9 | 31.3 | 28.9 | 24.9 | — | 207 | 212 | 178 | 183 |
| Operating income | 49.6 | 76.2 | 179 | 0.3 | 9.0 | — | -223 | -261 | -177 | -227 |
| EBIT | 49.6 | 76.2 | 179 | 0.3 | 9.0 | — | -223 | -261 | -177 | -227 |
| EBITDA | 84.0 | 109 | 209 | 28.3 | 41.8 | — | -194 | -236 | -153 | -209 |
| Interest expense | 6.4 | 8.1 | 9.2 | 4.8 | 3.3 | — | 12.5 | 10.0 | 3.3 | 1.2 |
| Pre-tax income | -119 | -470 | -0.1 | -42.9 | -128 | — | -245 | -202 | -230 | -367 |
| Income tax | 9.9 | 37.4 | 24.4 | -6.8 | 9.8 | — | 1.1 | -7.5 | 3.8 | -5.0 |
| Net income | -129 | -507 | -25.5 | 3,137 | -175 | — | -93.6 | -91.3 | -136 | -268 |
| Net income to common shareholders | -129 | -507 | -25.5 | 3,137 | -175 | — | -93.6 | -91.3 | -136 | -268 |
| Basic EPS | -0.06 | -0.23 | -0.01 | 1.48 | -0.08 | — | -0.04 | -0.04 | -0.06 | -0.13 |
| Diluted EPS | -0.06 | -0.23 | -0.02 | 1.40 | -0.08 | — | -0.04 | -0.04 | -0.06 | -0.13 |
| Average shares (basic) | 2,183 | 2,180 | 2,155 | 2,126 | 2,117 | — | 2,107 | 2,103 | 2,091 | 2,085 |
| Average shares (diluted) | 2,183 | 2,228 | 2,156 | 2,240 | 2,117 | — | 2,107 | 2,103 | 2,091 | 2,085 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4,853 | 5,278 | 3,387 | 2,546 | 2,234 | 1,447 | 889 | 917 | 504 | 226 |
| Current assets | 1,079 | 835 | 2,353 | 1,765 | 1,639 | 993 | 554 | 679 | 398 | 164 |
| Cash and equivalents | 142 | 132 | 1,446 | 1,024 | 1,181 | 629 | 252 | 495 | 124 | 136 |
| Short-term investments | 170 | 264 | 376 | 229 | 223 | 137 | 149 | — | 3.1 | — |
| Receivables | 159 | 136 | 300 | 170 | 167 | 164 | 87.9 | 82.6 | 260 | 21.0 |
| Inventory | 39.6 | 31.1 | 53.3 | 59.9 | 44.4 | 31.7 | 16.5 | 12.4 | 6.9 | 4.2 |
| Net property, plant and equipment | 613 | 596 | 729 | 625 | 487 | 379 | 266 | 158 | 80.5 | 43.7 |
| Goodwill | 1.4 | 1.3 | 1.4 | 2.5 | 14.2 | 14.1 | 15.2 | 15.3 | 1.5 | 1.4 |
| Other intangible assets | 13.3 | 13.0 | 18.6 | 23.8 | 26.4 | 26.0 | 25.5 | 19.6 | 2.5 | 2.1 |
| Long-term investments | 3,111 | 3,790 | 85.4 | 16.0 | 18.5 | 14.0 | 7.3 | 11.3 | 1.8 | — |
| Current liabilities | 720 | 781 | 495 | 546 | 413 | 328 | 225 | 154 | 273 | 39.2 |
| Accounts payable | 36.8 | 29.8 | 40.0 | 55.8 | 30.2 | 23.4 | 17.6 | 11.2 | 8.2 | 4.4 |
| Long-term debt | 85.9 | 96.7 | 713 | 567 | 382 | 1.3 | 1.7 | — | — | — |
| Total debt | 150 | 161 | 786 | 623 | 417 | 10.9 | 7.7 | — | — | — |
| Total liabilities | 889 | 955 | 1,343 | 1,184 | 846 | 632 | 517 | 424 | 276 | 42.0 |
| Total equity (incl. minority) | 3,965 | 4,323 | 2,044 | 1,363 | 1,388 | 816 | 372 | 493 | 228 | 184 |
| Retained earnings | 1,831 | 2,364 | -598 | -502 | -275 | -175 | 29.9 | 127 | 105 | 81.3 |
| Minority interest | 5.4 | 2.2 | 653 | 352 | 342 | -86.1 | -10.5 | 14.6 | 10.5 | 6.4 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4,787 | 4,853 | 5,435 | 5,278 | 3,332 | 3,387 | 3,384 | 2,546 | 2,144 | 2,234 |
| Current assets | 1,114 | 1,079 | 1,177 | 835 | 2,214 | 2,353 | 2,468 | 1,765 | 1,498 | 1,639 |
| Cash and equivalents | 196 | 142 | 293 | 132 | 399 | 1,446 | 1,397 | 1,024 | 782 | 1,181 |
| Short-term investments | 235 | 170 | 104 | 264 | 1,328 | 376 | 500 | 229 | 458 | 223 |
| Receivables | 157 | 159 | 132 | 136 | 235 | 300 | 208 | 170 | 102 | 167 |
| Inventory | 45.3 | 39.6 | 38.8 | 31.1 | 50.9 | 53.3 | 51.5 | 59.9 | 49.9 | 44.4 |
| Net property, plant and equipment | 639 | 613 | 598 | 596 | 814 | 729 | 686 | 625 | 549 | 487 |
| Goodwill | 1.4 | 1.4 | 1.3 | 1.3 | 1.3 | 1.4 | 2.5 | 2.5 | 14.1 | 14.2 |
| Other intangible assets | 13.4 | 13.3 | 12.8 | 13.0 | 16.1 | 18.6 | 22.6 | 23.8 | 25.5 | 26.4 |
| Long-term investments | 2,987 | 3,111 | 3,609 | 3,790 | 96.7 | 85.4 | 35.9 | 16.0 | 18.7 | 18.5 |
| Current liabilities | 727 | 720 | 601 | 781 | 533 | 495 | 438 | 546 | 513 | 413 |
| Accounts payable | 42.3 | 36.8 | 51.7 | 29.8 | 59.2 | 40.0 | 40.3 | 55.8 | 32.9 | 30.2 |
| Long-term debt | 90.1 | 85.9 | 330 | 96.7 | 846 | 713 | 771 | 567 | 461 | 382 |
| Total debt | 150 | 150 | 411 | 161 | 958 | 786 | 847 | 623 | 495 | 417 |
| Total liabilities | 894 | 889 | 1,013 | 955 | 1,508 | 1,343 | 1,298 | 1,184 | 1,256 | 846 |
| Total equity (incl. minority) | 3,893 | 3,965 | 4,421 | 4,323 | 1,824 | 2,044 | 2,086 | 1,363 | 888 | 1,388 |
| Retained earnings | 1,702 | 1,831 | 2,339 | 2,364 | -773 | -598 | -596 | -502 | -654 | -275 |
| Minority interest | 5.5 | 5.4 | 5.4 | 2.2 | 609 | 653 | 731 | 352 | 131 | 342 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 326 | 75.6 | -287 | -120 | -137 | -151 | -30.0 | 308 | 21.4 | 33.3 |
| Depreciation and amortization | 73.3 | 75.7 | 71.9 | 61.2 | 45.9 | 32.3 | 20.4 | 12.3 | 6.6 | 5.0 |
| Capital expenditure | -82.1 | -196 | -252 | -216 | -133 | -122 | -110 | -70.8 | -29.2 | -8.6 |
| Investing cash flow | -172 | -1,456 | -358 | -443 | -213 | -100 | -209 | -194 | -36.5 | -8.3 |
| Financing cash flow | -145 | 66.5 | 1,068 | 419 | 902 | 624 | -2.8 | 257 | 2.0 | 8.5 |
| Dividends paid | — | — | — | — | — | — | — | — | -2.6 | — |
| Share repurchases | -225 | 0.0 | — | — | 0.0 | -9.5 | -7.8 | -11.5 | — | — |
| Debt issued | 219 | 103 | 74.4 | 33.1 | 26.0 | 52.9 | 27.2 | 10.5 | — | — |
| Debt repaid | -142 | -67.7 | -34.1 | -7.4 | -74.9 | -30.6 | -20.4 | — | — | -1.2 |
| Effect of exchange rates | 1.8 | -0.2 | -1.2 | -12.7 | -0.9 | 3.7 | -0.8 | -0.3 | 0.4 | -0.7 |
| Net change in cash | 10.5 | -1,314 | 422 | -157 | 552 | 377 | -242 | 371 | -12.6 | 32.7 |
| Free cash flow | 243 | -120 | -539 | -336 | -270 | — | — | — | — | — |
| Levered free cash flow | -67.8 | 425 | -305 | -343 | -176 | -224 | -113 | -20.2 | -5.2 | 24.0 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 46.7 | 92.9 | 233 | -4.2 | 79.9 | — | -187 | -58.3 | -62.0 | -101 |
| Depreciation and amortization | 40.4 | 38.4 | 34.9 | 35.4 | 40.3 | — | 35.5 | 31.2 | 30.0 | 22.9 |
| Capital expenditure | -47.7 | -43.9 | -38.3 | -61.8 | -134 | — | -133 | -142 | -73.9 | -64.3 |
| Investing cash flow | 12.7 | -73.3 | -98.6 | -323 | -1,133 | — | -455 | -106 | -337 | -43.6 |
| Financing cash flow | -4.5 | -171 | 26.4 | 61.0 | 5.6 | — | 1,020 | 411 | 8.2 | 369 |
| Debt issued | 98.6 | 136 | 83.4 | 77.4 | 25.2 | — | 12.3 | 26.6 | 6.5 | 0.0 |
| Debt repaid | -111 | -103 | -38.9 | -20.3 | -47.4 | — | -14.7 | -4.4 | -3.0 | -21.1 |
| Effect of exchange rates | -0.9 | 1.0 | 0.8 | -0.7 | 0.5 | — | -5.0 | -4.6 | -8.1 | -1.2 |
| Net change in cash | 53.9 | -151 | 161 | -267 | -1,047 | — | 373 | 242 | -399 | 223 |
| Free cash flow | -1.0 | 49.0 | 194 | -66.0 | -54.2 | — | -320 | -200 | -136 | -165 |
| Levered free cash flow | 1.1 | -380 | -162 | 314 | 112 | — | -340 | -306 | -37.0 | -214 |
Financial statements of similar companies
Companies in the group: same industry, similar size
